{
    "Trade/Device Name(s)": [
        "EliA Cardiolipin IgG",
        "EliA Cardiolipin IgM",
        "EliA \u03b22-Glycoprotein I IgG",
        "EliA \u03b22-Glycoprotein I IgM",
        "EliA APS Positive Control 100",
        "EliA APS Positive Control 250"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K091845",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020752",
        "K020758",
        "K040449",
        "K040451"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MID",
        "MSV",
        "JJY"
    ],
    "Summary Letter Date": "June 3, 2010",
    "Summary Letter Received Date": "June 4, 2010",
    "Submission Date": "May 27, 2009",
    "Regulation Number(s)": [
        "21CFR866.5660",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Multiple Autoantibodies Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Cardiolipin IgG antibody",
        "Cardiolipin IgM antibody",
        "\u03b22-Glycoprotein I IgG antibody",
        "\u03b22-Glycoprotein I IgM antibody"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay (EIA)"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for EliA Cardiolipin and \u03b22-Glycoprotein I IgG/IgM immunoassays and APS Positive Controls on Phadia 100/250 for autoimmune diagnostics",
    "Indications for Use Summary": "For in vitro semi-quantitative measurement of IgG and IgM antibodies to cardiolipin and \u03b22-Glycoprotein I in human serum and plasma to aid in diagnosis of antiphospholipid syndrome and related thrombotic disorders, and for control monitoring on Phadia 100/250 with EliA IgG/IgM methods.",
    "fda_folder": "Immunology"
}